Whalesbook
Shree Ganesh Biotech reported a net profit of ₹0.38 Crores for fiscal year 2026, despite total income falling 73.59% to ₹6.44 Crores. The fourth quarter ended with a net loss of ₹0.15 Crores as expenses exceeded income, while inventories surged to ₹11.73 Crores.
Financial Results Filing
The company announced its standalone financial results for the fiscal year and quarter ending March 31, 2026. For the full year FY26, Shree Ganesh Biotech posted a net profit of ₹0.38 Crores on total income of ₹6.44 Crores. This marks a significant year-over-year revenue decline of 73.59% from ₹24.39 Crores in FY25. The fourth quarter (Q4 FY26) recorded a net loss of ₹0.15 Crores, with total income at ₹2.40 Crores and total expenses at ₹2.55 Crores. Auditors issued an unmodified opinion on the financial statements.
Implications for Investors
The sharp 73.59% year-on-year fall in annual income indicates severe operational challenges or market difficulties. Combined with a net loss in the most recent quarter, this raises questions about the company's ability to generate revenue and maintain profitability. The substantial increase in inventory levels to ₹11.73 Crores from ₹2.89 Crores the previous year suggests potential sales slowdown or issues selling existing stock.
Company Business and History
Shree Ganesh Biotech operates in plant tissue culture, horticulture, and the production of ornamental and agricultural crops. The company has historically experienced volatile financial results and ongoing revenue difficulties. A notable temporary revenue spike in FY25 to ₹24.39 Crores was followed by the sharp decline in FY26, suggesting challenges in maintaining business operations and achieving growth.
Current Situation
Shareholders are observing a company facing significant revenue contraction. The ₹0.38 Crores FY26 profit is overshadowed by the substantial revenue drop and a quarterly loss. The large buildup in inventory needs careful management to prevent potential write-offs or cash flow problems. Sustained operational performance and a clear strategy to reverse the revenue decline are crucial for the company's future.
Key Risks
- Continued revenue contraction and failure to boost sales.
- Potential for ongoing quarterly losses and increased financial pressure.
- Difficulties in selling the significantly increased inventory.
- A large portion of non-current loan assets on the balance sheet, amounting to ₹42.75 Crores.
Industry Context
Direct peers for Shree Ganesh Biotech's specific niche and size are limited. However, companies like Kaveri Seed Company and Advanta Enterprises operate in the broader agri-business and seed sectors. These larger companies also navigate industry trends and market dynamics, though their scale and business diversity differ considerably.
Key Financial Metrics
- Annual Total Income: ₹6.44 Crores (Standalone, FY26)
- Annual Net Profit: ₹0.38 Crores (Standalone, FY26)
- Quarterly Net Loss: ₹0.15 Crores (Standalone, Q4 FY26)
- Inventory Levels: ₹11.73 Crores (Standalone, as of Mar 31, 2026)
Looking Ahead
Investors will watch for management commentary on the reasons for the revenue decline and inventory surge. Key areas to track include strategies for inventory management and sales growth, the performance outlook for Q1 FY27, and any steps taken to improve operational performance and control expenses. Updates on the company's balance sheet, particularly loan assets, will also be important.